Skip to content
Peptigraph home
Shop Peptides50% off*

Can retatrutide cause pancreatitis?

Acute pancreatitis was recorded as a serious event in single participants in phase 2 registries. In the obesity dose-finding registry it affected 1 of 62 in the top-dose step-up arm and 0 of 70 on placebo; counts this small cannot show cause.

GLP-1 / GIP / glucagon triple agonistUpdated

Short answer

Acute pancreatitis was recorded as a serious event in single participants in phase 2 registries. In the obesity dose-finding registry it affected 1 of 62 in the top-dose step-up arm and 0 of 70 on placebo; counts this small cannot show cause.[1]

In the diabetes dose-finding registry, acute pancreatitis affected 1 of 47 in the lowest-dose arm and 1 of 26 in a mid-dose arm, against 0 of 45 on placebo.[2]

Who the trials left out

The late-stage obesity trial excluded anyone who had had pancreatitis, so its results say little about people with that history.[3]

The obesity dose-finding trial excluded a history of acute or chronic pancreatitis and symptomatic gallbladder disease.[1]

More questions on Retatrutide

Can retatrutide cause cancer?Can retatrutide cause high blood pressure?Can retatrutide cause joint pain?Can women take retatrutide?Can you build muscle on retatrutide?Can you drink alcohol while on retatrutide?

More on Retatrutide

Side effectsWhat labels and studies report, and what is unknown.Retatrutide overview

Sources

  1. 1A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related ComorbiditiesClinicalTrials.gov (U.S. National Library of Medicine) · 2021clinicaltrials.govAccessed 2 Oct 2026
  2. 2A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 DiabetesClinicalTrials.gov (U.S. National Library of Medicine) · 2021clinicaltrials.govAccessed 2 Oct 2026
  3. 3A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)ClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.